The Lupus Science & Medicine® podcast is your premier source for the latest insights and developments in lupus and related diseases. Each episode features in-depth interviews with authors and leading experts, covering the newest advances in lupus research and treatments. Lupus Science & Medicine® - lupus.bmj.com - is an esteemed international journal from the BMJ Group and the Lupus Foundation of America (LFA). The journal publishes basic, clinical, translational, and epidemiological studies of all aspects of lupus and related diseases. Subscribe now or listen on your favourite podcast platform to enhance your understanding of lupus. Podcast hosted by: Dr. Anna Wolska, The Lupus Foundation of America, USA
Join host Dr. Anna Wolska as she explores a new study in Lupus Science & Medicine on how positive psychosocial factors—such as resilience, self-efficacy, and emotional support—can reduce stress in people with systemic lupus erythematosus (SLE). In this episode, she speaks with Drs. Kimberly DeQuattro and Sarah Patterson about these factors' protective effects, even for those with trauma histories, and discusses the study's impl...
Join Dr. Anna Wloska from the Lupus foundation of America and Drs. Peter Lipsky and Amerie Grammer as they discuss the effectivenss of krill oil in reducing disease activity in systemic lupus erythematosus. In this episode, our guest highlight the potential therapeutic benefits of restoring omega-3 fatty acids in patients with SLE and the potency and efficacy of omegga-3s found in krill oil versus other sources.
Join Dr. Anna Wolska from the Lupus Foundation of America and Dr. Laurent Arnaud, Professor of Rheumatology at the Department of Rheumatology, University Hospitals of Strasbourg as they discuss systemic lupus erythematosus (SLE) clinical trials. In this episode, Dr. Arnaud highlights the complexities of drug approval processes in lupus, the pivotal role of large-scale phase three randomized trials and critical outcome measures in t...
Join Dr. Anna Wolska from the Lupus Foundation of America as she delves into a groundbreaking discussion with Dr. Stephen Balevic focused on hydroxychloroquine blood levels and understanding medication adherence in lupus patients. In this episode, Dr. Balevic, a rheumatologist and clinical pharmacologist from Duke University, explains the nuances of interpreting hydroxychloroquine levels, the challenges of ensuring patient adherenc...
Join Dr. Anna Wolska and Dr. May Choi as they explore the role of Artificial Intelligence (AI) and Machine Learning (ML) in guiding diagnostic and care decisions for systemic lupus erythematosus (SLE). Dr. Choi delves into key elements of machine learning and its potential impact on improving outcomes, particularly in underserved populations. She also discusses various types of machine learning, such as deep learning, supervised le...
Join Dr. Anna Wolska and Dr. Jim Posada as they delve into the intricacies of RNAse therapy in the management of Systemic Lupus Erythematosus (SLE). In this podcast episode, Dr. Posada describes the groundbreaking study evaluating the efficacy of RSLV-132, a novel RNAse molecule fused to human IgG1 Fc, in reducing chronic inflammation associated with cutaneous lupus. Key findings from the clinical trial reveal that patients with mo...
Dr. Anna Wolska engages in a conversation with Dr. Shivani Garg and Dr. Christie Bartels to delve into the development and implementation of HCQ-SAFE. This innovative decision-aid is designed to empower individuals living with lupus to engage in shared-decision making. The authors discuss the importance of streamlining and enhancing shared decision-making dynamics between patients and healthcare providers regarding the utilization ...
Dr. Anna Wolska speaks to Dr. Michael Belmont and Devyn Zaminski to discuss the importance of dual dsDNA testing in order to full understand disease activity. In this study, they made the observation that there is a large amount of discordance in anti-dsDNA antibodies assays. Misinterpretation or errors in anti- dsDNA antibody testing could have negative implications on long term outcomes in people living with SLE.
Dr. Anna Wolska engages in a discussion with renowned experts, Dr. Catharina Lindholm and Dr. David Jayne, to explore findings from the phase II TULIP Lupus Nephritis trial. This in-depth conversation centers on results from a clinical trial where they evaluated the efficacy of intensified anifrolumab treatment in individuals with active lupus nephritis.
Read the article: http://dx.doi.org/10.1136/lupus-2023-000910
Dr. Anna Wolska sits down with experts, Dr. Michelle Petri and Dr. Nick Ballew, analyzing the effectiveness of SLE treatments Belimumab and Anifrolumab. The conversation delves into their meticulous study, where they examined the 52-week SLE Responder Index (SRI)-4 responses, providing crucial data for informed lupus patient care. The study data, based on rigorous randomized trials and systematic literature reviews, offers clinici...
Dr. Anna Wolska from the Lupus Foundation of America interviews Drs. Ana Malvar and Brad Rovin. They discuss using repeat tissue biopsies to understand progression of lupus nephritis over time. They offer conjecture that both immunosuppression as well as mitigation of tissue fibrosis, resulting from inflammatory resolution, are needed in order to preserve kidney function and prevent progression to kidney failure.
Dr. Anna Wolska from the Lupus Foundation of America interviews Drs. Anca Askanase and Joan Merrill, the developers of the LFA-REAL tool. Together, they discuss the importance of using a tool like LFA-REAL to understand how clinician and patient reported outcomes are essential for understanding efficacy and effectiveness of experimental therapeutics developed to treat people living with lupus.
Read the article: http://dx.doi.org/...
Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Amrie Grammer and Dr. Peter Lipsky from AMPEL BioSolutions. Together they describe the molecular endotypes of Type 1 and Type 2 Systemic Lupus Erythematosus. This episode uncovers the distinct molecular profiles of these SLE types and paves the way for personalized treatment approaches based on these classifications.
Link to published paper: https://lupus.bmj.com...
Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Ian Bruce, from the University of Manchester in the UK. Dr Bruce discusses the time to onset of clinical response to Anifrolumab in patients with Systemic Lupus Erythematosus. The episode delves into pooled data from two significant Phase III trials, TULIP-1 and TULIP-2, offering listeners a deep understanding of the effectiveness and timeline of Anifrolumab treatm...
Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Andrea Fava from Johns Hopkins University about Belimumab treatment in lupus nephritis. Dr Fava elucidates on the correlation between the decrease in urinary CD163 levels and the response to Belimumab treatment in Lupus Nephritis trials. The conversation provides important insights into the efficacy of this treatment option and potential biomarker use for personali...
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Join Holly and Tracy as they bring you the greatest and strangest Stuff You Missed In History Class in this podcast by iHeartRadio.
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations.
The Clay Travis and Buck Sexton Show. Clay Travis and Buck Sexton tackle the biggest stories in news, politics and current events with intelligence and humor. From the border crisis, to the madness of cancel culture and far-left missteps, Clay and Buck guide listeners through the latest headlines and hot topics with fun and entertaining conversations and opinions.
If you can never get enough true crime... Congratulations, you’ve found your people.